Evidence map›Paper›PMID 27649551›Full record

Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.

Chad Tang, James W Welsh, Patricia de Groot, Erminia Massarelli, Joe Y Chang, Kenneth R Hess, Sreyashi Basu, Michael A Curran, Maria E Cabanillas, Vivek Subbiah and 10 more

3 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase IClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 214 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
214citing papers in PubMed, 8 pooled it
17.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03532737 phase2unknown statusnot on this mapstarted 2018, after this paper: background citation

Phase II Non-Randomised Controlled Trial Of Concomitant Immune Check Point Inhibitor With Radiotherapy And Chemotherapy Or Cetuximab In Advanced Non Metastatic Head And Neck Cancer

TypeinterventionalSponsorKuwait Cancer Control CenterRan2018 to 2025Enrolled50ConditionsLocally Advanced Head and Neck CancerArmsPembrolizumab
NCT03927898 phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

Phase II Study of Toripalimab (JS001) Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis

TypeinterventionalSponsorChinese Academy of Medical SciencesRan2019 to 2021Enrolled40ConditionsMetastatic Colorectal CancerArmsToripalimab, Stereotactic Body Radiotherapy
NCT05229614 phase2recruitingnot on this mapstarted 2022, after this paper: background citation

Immune Checkpoint Inhibitors and Carbon iON Radiotherapy In Solid Cancers With Stable Disease

TypeinterventionalSponsorCNAO National Center of Oncological HadrontherapyRan2022 to 2026Enrolled27ConditionsNon Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Urothelial CarcinomaArmsCarbon Ion Therapy, Immunotherapy (Pembrolizumab)
3 · Its place in the literature

Who cites it

214 citing papers in PubMed, 8 syntheses or guidelines pooled it, 311 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Trial
  16. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2017
    Trial
  17. Innovative immunotherapeutic strategies for thyroid cancer: challenges and opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  18. Review
  19. Review
  20. Review

154 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 1 institution in 1 country.

Chad TangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. ctang1@mdanderson.org jwelsh@mdanderson.org dshong@mdanderson.org.
James W WelshDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. ctang1@mdanderson.org jwelsh@mdanderson.org dshong@mdanderson.org.
Patricia de GrootDepartment of Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Erminia MassarelliDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Joe Y ChangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kenneth R HessDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sreyashi BasuDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Michael A CurranDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Maria E CabanillasDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Vivek SubbiahDepartment of Investigational Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Siqing FuDepartment of Investigational Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Apostolia M TsimberidouDepartment of Investigational Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Daniel KarpDepartment of Investigational Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Daniel R GomezDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Adi DiabDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ritsuko KomakiDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
John V HeymachDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Padmanee SharmaDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Aung NaingDepartment of Investigational Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
David S HongDepartment of Investigational Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. ctang1@mdanderson.org jwelsh@mdanderson.org dshong@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Center for Clinical and Translational Sciences (CCTS)UL1TR000371 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$13.4M
NCATS NIH HHS UL1 TR000371NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCombined Modality TherapyFemaleFlow CytometryHumansIpilimumabLiverLiver NeoplasmsLungLung NeoplasmsMaleBiomarkers, TumorIpilimumab

Identifiers

PMID27649551
PMCPMC5355002
OpenAlexW2521278016

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.